Berkshire Hathaway Vice-Chairman Charlie Munger had some harsh words to say about Valeant Pharmaceuticals. » Read More
I think he will find his base at Valeant, says Fred Hassan, Warburg Pincus, talking about Joseph Papa, the newly appointed CEO of Valeant.
CNBC's Meg Tirrell reports on an FDA advisory committee's vote to decline the sale of an experimental drug to treat Duchenne muscular dystrophy.
Inventor of aspirin and maker of Yasmin birth control pills says it still expects adjusted EBITDA to increase this year.
Advisers to the FDA voted on Monday not to recommend approval of possibly the first drug for Duchenne muscular dystrophy, the New York Times reports.
Sarepta interim CEO Ed Kaye reacts to FDA panel's negative decision on data supporting approval of Duchenne muscular dystrophy drug.
CNBC's Meg Tirrell looks into Valeant Pharma's appointment of Joseph Papa to CEO, as well as Sarepta's showdown with the FDA over a muscular dystrophy drug.
Perrigo plummeted 13 percent in the premarket Monday after issuing very weak guidance.
Sarepta Therapeutics's Eteplirsen is in front of the FDA advisory committee today for a vote on whether the drug is effective in treating Duchenne muscular dystrophy, reports CNBC's Meg Tirrell.
Theranos offers a reminder of the perils of investing in Silicon Valley, where it's common for founders to control a company, the NYT reports.
Sarepta was down sharply a day after an FDA advisory committee voted against recommending the company's Duchenne muscular dystrophy drug.
CNBC's Meg Tirrell reports on the possibility of Perrigo CEO Joseph Papa heading over to Valeant, as well as biotech firm Interxon feeling some pressure after the release of a report calling it 'the new Theranos.'
Raghuram Selvaraju, H.C. Wainwright senior biotechnology analyst, talks about Valeant offering the CEO position to Perrigo's Joseph Papa.
Jim Stewart, CNBC Contributor and The New York Times Columnist, talks about the struggling relationship between Walgreens and Theranos.
Drugmaker Valeant Pharmaceuticals is seeking to appoint Perrigo boss Joseph Papa as its new chief executive, a source familiar with the matter said.
Pharma company Valeant has been under fire recently, but this investor says it's a buy.
Walgreen agreed to remove stale shelf tags within 36 hours and end the use of "last chance" or "clearance" tags to promote items that are neither.
Shares of Sarepta Therapeutics plunge after the FDA maintains its "negative" outlook on the company's drug for a rare muscle-wasting disorder.
Actelion CEO Jean-Paul Clozel discusses its latest drug developments and why 2016’s first quarter was “key” for the company.
Actelion CEO, Jean-Paul Clozel talks about the changing face of the M&A space for pharmaceuticals and biotech and clearing the air on what really happened with ZS Pharma.
Dick Kovacevich defended the embattled lab testing start-up's boss, Elizabeth Holmes, saying her treatment recently has been unfair.
Get the best of CNBC in your inbox